ArticleDrug design, development and therapy2024
Effectiveness of Spironolactone in Reducing Osteoporosis and Future Fracture Risk in Middle-Aged and Elderly Hypertensive Patients.
Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A physiology-based mathematical model of the renin-angiotensin system, bone remodeling, and calcium homeostasis: Effects of estrogen and renin-angiotensin system inhibitors.PLoS computational biology · 2026Article
- Causal effects among hypertension, osteoporosis, and metabolites: A Mendelian randomization study.Journal of the Chinese Medical Association : JCMA · 2026Article
- Bone microarchitectural degradation in hypertensive patients: a population-based study.Archives of osteoporosis · 2026Article
- Can Blood Cell Count-Based Inflammatory Markers Reflect the Risk of Osteoporosis? A Cross-Sectional and Genetic Analysis.Immunity, inflammation and disease · 2026Article
- REACT (Real-world Emulated Clinical Trials): A Framework for Drug Repurposing Applied to Osteoporotic Fractures.medRxiv : the preprint server for health sciences · 2026Article
- REACT (Real-world Emulated Clinical Trials): A Framework for Drug Repurposing Applied to Osteoporotic Fractures.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Folic Acid Therapy is Associated with a Lower Risk of Incident Diabetes and Better Glycemic Status in Patients with Coronary Heart Disease: Findings from a Multicenter Propensity Score-Matched Analysis.Drug design, development and therapy · 2026Article
- Association of CVAI with BMD, FRAX scores, and osteoporosis risk in Chinese elderly patients with hypertension.Scientific reports · 2025Article
- Association between conicity index (C-index), relative fat mass (RFM), and osteoarthritis (OA): evidence from NHANES 2003-2018.Lipids in health and disease · 2025Article
- Association between niacin intake and osteoarthritis in the US population based on NHANES 1999-2018.Scientific reports · 2025Article
- Serum Uric Acid and Bone Health in Middle-Aged and Elderly Hypertensive Patients: A Potential U-Shaped Association and Implications for Future Fracture Risk.Metabolites · 2025Article
- Exploring the Causal Relationship Between Osteoporosis and Rheumatoid Arthritis: A Bidirectional Mendelian Randomization Study.Orthopedic research and reviews · 2025Article
- Comprehensive Analysis of the Role of Metabolic Features in Osteoporosis: A Multi-Omics Analysis.International journal of general medicine · 2025Article
- Plasma Aldosterone Elevation in Hypertensive Patients and Association with Urinary Stone Formation: A Large-Scale Population Study from Northwest China.Clinical epidemiology · 2025Article
- Pharmacovigilance-related events, disease burden and overall efficiency of care in european countries, 1990-2021.Frontiers in pharmacology · 2025Article
- Association of plasma aldosterone concentration with peripheral artery disease in hypertensive patients: insights from a large cross-sectional analysis.Frontiers in cardiovascular medicine · 2025Article
- Analysis of the Current Status of Self-Management Behaviors and Factors Affecting Self-Management in Elderly Empty Nesters with Comorbid Hypertension and Type 2 Diabetes Mellitus, a Cross-Sectional Study From the Community.Risk management and healthcare policy · 2025Article
- Osteoporosis diagnosis and ingredients of prescription medications: a population-based study.Frontiers in pharmacology · 2025Article
- A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.Frontiers in pharmacology · 2024Article
- Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population.International journal of general medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: While the role of aldosterone in bone metabolism is well established, the specific effects of the widely used aldosterone antagonist, spironolactone, on bone health are not fully understood. This study aimed to investigate the effects of spironolactone on osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients, revealing its potential benefits for bone health. Methods: Propensity score matching was employed in this study to create matched groups of spironolactone users and non-users at a 1:4 ratio. We investigated the association between spironolactone use and the risk of osteoporosis using multivariate logistic regression analysis. Furthermore, we conducted multivariate linear regression analysis to explore the relationship between cumulative dosage and the FRAX score. Subgroup analysis was also performed to assess the effects under different stratification conditions. Results: In both pre-match and post-match analyses, multivariable logistic regression revealed a significant reduction in the risk of osteoporosis in the spironolactone usage group (pre-match: odds ratios [OR] 0.406, 95% confidence interval [CI], 0.280-0.588; post-match: OR 0.385, 95% CI, 0.259-0.571). Furthermore, post-match multivariable linear regression demonstrated a clear negative correlation between cumulative spironolactone dosage and the FRAX score. Subgroup analyses consistently supported these findings. Conclusion: This study offers evidence supporting the significant positive impact of the antihypertensive drug spironolactone on bone health, resulting in a substantial reduction in the risk of osteoporosis and future fractures in hypertensive patients. Future research should consider conducting large-scale, multicenter, randomized controlled trials to further investigate the long-term effects of spironolactone on bone health in hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.